Loading...
Loading...
Teva Women's Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical
Industries Ltd.
TEVA, today announced findings from a Phase III
clinical trial of Milprosa^TM (progesterone), an investigational weekly
progesterone vaginal ring for luteal supplementation in women undergoing in
vitro fertilization (IVF). These data were presented as an oral presentation
at the 68^th Annual Meeting of the American Society for Reproductive Medicine
(ASRM).
Data from a randomized, single-blind trial assessing the pregnancy rate of
Milprosa™ versus daily 8 percent progesterone gel for luteal supplementation
in women undergoing embryo transfer during IVF at days three and five were
presented. Results showed clinical pregnancy rates for Milprosa™ were similar
to progesterone gel, regardless of the day the embryos were returned to the
uterus. Researchers concluded that Milprosa™ is effective in luteal
supplementation in IVF and that clinical pregnancy rates were similar for the
vaginal ring and 8 percent progesterone gel.^1
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in